Weight-Loss drug may curb alcohol cravings in fatty liver patients
NCT ID NCT06546384
First seen Mar 12, 2026 · Last updated May 08, 2026 · Updated 7 times
Summary
This study tests whether semaglutide (a GLP-1 drug used for diabetes and weight loss) can help people with obesity and fatty liver disease stop drinking alcohol. About 64 participants will receive either semaglutide or a placebo, plus counseling, for 16 weeks. The main goal is to see if more people in the drug group achieve complete alcohol abstinence.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALCOHOL USE DISORDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Hospital Bern
Bern, 3010, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.